ATM and cancer: Hong et al. [24] found that Bortezomib could induce the generation of intracellular reactive oxygen species (ROS) and ATM phosphorylation, leading to G2-M phase arrest in CRC cells, highlighting its potential in cell cycle blockage and anti-cancer therapy.